Search

Your search keyword '"Dal, Mehmet"' showing total 592 results
Start Over Author "Dal, Mehmet"
592 results on '"Dal, Mehmet"'

4. Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

Author

Dal, Mehmet Sinan, Ulu, Bahar Uncu, Uzay, Ant, Akay, Olga Meltem, Beşışık, Sevgi, Yenerel, Mustafa Nuri, Çelik, Serhat, Kaynar, Leylagül, Yücel, Orhan Kemal, Deveci, Burak, Sönmez, Mehmet, Mehtap, Özgür, Beköz, Hüseyin Saffet, Sunu, Cenk, Salim, Ozan, Ulaş, Turgay, Kartı, Sami, Altuntaş, Fevzi, Ferhanoğlu, Burhan, and Tuğlular, Tülin Fırat

Published
2023
Full Text
View/download PDF

6. International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report

Author

Ozatli, Duzgun, Giden, Aslı Odabaşı, Erkurt, Mehmet Ali, Korkmaz, Serdal, Basci, Semih, Ulas, Turgay, Turgut, Burhan, Yigenoglu, Tugce Nur, Hacibekiroglu, Tuba, Basturk, Abdulkadir, Dal, Mehmet Sinan, Namdaroglu, Sinem, Hindilerden, Fehmi, Hacioglu, Sibel Kabukcu, Cagliyan, Gulsum Akgun, Ilhan, Gul, Kacmaz, Murat, Uysal, Ayşe, Merter, Mustafa, Ekinci, Omer, Dursun, Fadime Ersoy, Tekinalp, Atakan, Demircioglu, Sinan, Sincan, Gulden, Acik, Didar Yanardag, Akdeniz, Aydan, Ucar, Mehmet Ali, Yeral, Mahmut, Ciftciler, Rafiye, Teke, Hava Uskudar, Umit, Elif Gulsum, Karakus, Abdullah, Bilen, Yusuf, Yokus, Osman, Albayrak, Murat, Demir, Cengiz, Okan, Vahap, Serefhanoglu, Songül, Kartı, Sami, Ozkurt, Zubeyde Nur, Eser, Bulent, Aydogdu, Ismet, Kuku, Irfan, Cagirgan, Seckin, Sonmez, Mehmet, Ozet, Gulsum, and Altuntas, Fevzi

Published
2023
Full Text
View/download PDF

8. The Real‐World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

Author

Akpinar, Seval, Dogu, Mehmet Hilmi, Celik, Serhat, Ekinci, Omer, Hindilerden, Ipek Yonal, Dal, Mehmet Sinan, Davulcu, Eren Arslan, Tekinalp, Atakan, Hindilerden, Fehmi, Ozcan, Busra Gokce, Hacibekiroglu, Tuba, Erkurt, Mehmet Ali, Bagci, Metin, Namdaroglu, Sinem, Korkmaz, Gulten, Bilgir, Oktay, Cagliyan, Gulsum Akgun, Ozturk, Hacer Berna Afacan, Serin, Istemi, Tiryaki, Tarık Onur, Ozatli, Duzgun, Korkmaz, Serdal, Ulas, Turgay, Eser, Bulent, Turgut, Burhan, and Altuntas, Fevzi

Published
2022
Full Text
View/download PDF

9. Role of WT1 in Measurable Residual Disease Follow-Up in the Post Allogeneic Stem Cell Transplant Setting.

Author

Namdaroğlu, Sinem, Başcı, Semih, Aslan Candır, Burcu, Yaman, Samet, Yiğenoğlu, Tuğçe Nur, Bahsi, Taha, Özcan, Nurgül, Dal, Mehmet Sinan, Kızıl Çakar, Merih, and Altuntaş, Fevzi

Subjects
HEMATOPOIETIC stem cell transplantation, HEMATOLOGIC malignancies, NEPHROBLASTOMA, ACUTE myeloid leukemia, STEM cell transplantation
Abstract

Objectives: The Wilms' tumor gene 1 (WT1) plays a critical role in cell development and the regulation of essential genes involved in cell growth and metabolism. In the context of hematopoietic tumors, including acute myeloid leukemia (AML), WT1 has been identified as a potential marker for measurable residual disease (MRD) assessment. Relapse after allogeneic hematopoietic stem cell transplantation (allo-SCT) remains a significant challenge in AML treatment, highlighting the importance of MRD monitoring for risk stratification and treatment decisions. This study aimed to investigate the clinical significance of WT1 as a molecular marker for MRD and its correlation with chimerism in AML patients post-allo-SCT setting. Methods: We have included 58 patients with WT1-expression-positive acute myeloid leukemia (AML) who received allo-SCT in our center between 2016–2022. The exclusion criteria are as follows: not having WT1 polymerase chain reaction (PCR) measurement at diagnosis, not receiving allo-SCT, and not having a serial measurement of WT1 post-transplant. Pre- and post-transplant assessments were made with flow cytometry, WT1 PCR, and bone marrow morphological evaluations. Statistical analyses were carried out to explore correlations between WT1 levels, MRD markers, and chimerism post-transplantation. Results: We found that WT1 had a significant correlation with flow cytometry and bone marrow morphological evaluation, but not with chimerism. Interestingly, high WT1 expressors exhibited a more robust correlation with chimerism compared to the general cohort. The negative predictive value for post-allo-SCT relapse was 91.8% for the whole WT1 cohort; for high WT1 expressors, it was similar, at 87.5%. The negative predictive value for post-allo-SCT relapse was high for the whole WT1 cohort; for high WT1 expressors, it was similar. The WT1 MRD assay showed a high negative predictive value for post-allo-SCT relapse, consistent across both the entire cohort (91.8%) and high WT1 expressors (87.5%). Conclusions: WT1 expression levels may serve as a valuable ancillary marker in MRD assessment and relapse prediction post-allo-SCT in AML patients, particularly for those lacking specific fusion genes or mutations. However, further large-scale, controlled studies are needed to standardize WT1 MRD assays and establish clear guidelines for their clinical application. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Trajectory Tracking of a Quadcopter Using Adaptive Neuro-Fuzzy Controller with Sliding Mode Learning Algorithm

Author

Kemik, Hasan, Dal, Mehmet Berkin, Oniz, Yesim, Kacprzyk, Janusz, Series Editor, Pal, Nikhil R., Advisory Editor, Bello Perez, Rafael, Advisory Editor, Corchado, Emilio S., Advisory Editor, Hagras, Hani, Advisory Editor, Kóczy, László T., Advisory Editor, Kreinovich, Vladik, Advisory Editor, Lin, Chin-Teng, Advisory Editor, Lu, Jie, Advisory Editor, Melin, Patricia, Advisory Editor, Nedjah, Nadia, Advisory Editor, Nguyen, Ngoc Thanh, Advisory Editor, Wang, Jun, Advisory Editor, Kahraman, Cengiz, editor, Cevik Onar, Sezi, editor, Oztaysi, Basar, editor, Sari, Irem Ucal, editor, Cebi, Selcuk, editor, and Tolga, A. Cagri, editor

Published
2021
Full Text
View/download PDF

21. Clinical characteristics and therapeutic outcomes of paroxysmal nocturnal hemoglobinuria patients in Turkey: a multicenter experience

Author

Goren Sahin, Deniz, Akay, Olga Meltem, Keklik, Muzaffer, Okan, Vahap, Karakus, Abdullah, Demir, Cengiz, Erkurt, Mehmet Ali, Ilkkilic, Kadir, Yildirim, Rahsan, Akgun Cagliyan, Gulsum, Aksu, Salih, Dogu, Mehmet Hilmi, Dal, Mehmet Sinan, Karakus, Volkan, Gemici, Ali Ihsan, Terzi, Hatice, Kelkitli, Engin, Sivgin, Serdar, Unal, Ali, Yilmaz, Mehmet, Ayyildiz, Orhan, Korkmaz, Serdal, Eser, Bulent, and Altuntas, Fevzi

Published
2021
Full Text
View/download PDF

23. Convalescent plasma therapy in patients with COVID-19

Author

Altuntas, Fevzi, Ata, Naim, Yigenoglu, Tugce Nur, Bascı, Semih, Dal, Mehmet Sinan, Korkmaz, Serdal, Namdaroglu, Sinem, Basturk, Abdulkadir, Hacıbekiroglu, Tuba, Dogu, Mehmet Hilmi, Berber, İlhami, Dal, Kursat, Kınık, Kerem, Haznedaroglu, İbrahim, Yılmaz, Fatma Meriç, Kılıç, İsa, Demircioğlu, Sinan, Yosunkaya, Alper, Erkurt, Mehmet Ali, Turgut, Burhan, Caglayan, Murat, and Celik, Osman

Published
2021
Full Text
View/download PDF

25. Brentuximab Vedotin Monotheraphy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data.

Author

Darçın, Tahir, Serin, İstemi, Ugur, Mehmet Can, Ekinci, Ömer, Hindilerden, İpek Yonal, Akpınar, Seval, Hacıbekiroglu, Tuba, Demircioğlu, Sinan, Gültürk, Emine, Albayrak, Murat, Aydoğdu, İsmet, Dal, Mehmet Sinan, Doğu, Mehmet Hilmi, Namdaroğlu, Sinem, Doğan, Ali, Nalçaci, Meliha, Turgut, Burhan, Başcı, Semih, and Altuntaş, Fevzi

Subjects
ANTIBODY-drug conjugates, LYMPHOMA treatment, ANTINEOPLASTIC agents, THROMBOCYTOPENIA, DISEASE progression
Abstract

Copyright of Hitit Medical Journal is the property of Hitit Medical Journal and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

26. Early Tapering of Cyclosporine Is Feasible in Haploidentical Stem Cell Transplantation: A Single Center Experience.

Author

Yaman, Samet, Başci, Semih, Bozan, Ersin, Seçilmiş, Sema, Candir, Burcu Aslan, Yiğenoğlu, Tuğçe Nur, Çakar, Merih Kızıl, Dal, Mehmet Sinan, and Altuntaş, Fevzi

Subjects
STEM cell transplantation, GRAFT versus host disease, HEMATOPOIETIC stem cell transplantation, BONE marrow transplantation, CYCLOSPORINE
Abstract

Introduction: Cyclosporine‐A (CsA) and post transplantation cyclophosphamide (PTCy) are common agents used for graft versus host disease (GVHD) prophylaxis in Haploidentical hematopoietic cell transplantation (haplo‐HCT). However, the impact of CsA cessation timing in the posttransplant setting on clinical outcomes is uncertain. We aimed to investigate the impact of a novel approach that integrated early CsA cessation with PTCy utilization. Patients and Methods: This study was a single arm retrospective study carried out at a tertiary referral hospital hematology and bone marrow transplantation center between 2009 and 2022. The patients who received haplo‐HCT with ATG, PTCy and CsA as GVHD prophylaxis were included. CsA was planned for cessation starting at day 45 to day 60. Acute and chronic GVHD were evaluated and graded. CsA blood concentrations and its impact on acute and chronic GVHD was evaluated. Results: Thirty‐one patients composed of 19 (61.3%) male and 12 (38.7%) female patients with a median age of 31 years (20–58). Busulfan and TBI based conditioning regimens were the most utilized regimens. The majority of donors were first degree relatives. Stem cell origin was peripheral blood for all patients. GVHD prophylaxis consisted of ATG, CsA and PTCy. Acute GVHD was observed in 9 (29%) cases, whereas chronic GVHD was seen in 3 (9.7%) cases, with 2 of them having overlapping GVHD. Age, gender, number of chemotherapy lines, transplant characteristics, infused CD34 cell count, and engraftment durations were similar among patients with and without GVHD. Patients with GVHD had similar 1st, 2nd, 3rd and 4th week CsA concentrations compared to patients without GVHD (p > 0.05). The presence of GVHD was not associated with worse progression free survival and overall survival (p = 0.6, p = 0.5, respectively). CMV reactivation was more common in the GVHD group. Conclusion: In the current study, we did not find an impact of CsA concentration on GVHD and post‐transplant outcomes in Haplo‐HCT setting. Therefore, together with the use of PTCy, early CsA cessation can be an option; further studies are needed to understand all aspects of this approach. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Inferior prognosis in poor mobilizing myeloma patients

Author

Yiğenoğlu, Tuğçe Nur, Başcı, Semih, Ulu, Bahar Uncu, Bakırtaş, Mehmet, Kılınç, Ali, Şahin, Derya, Darçın, Tahir, Yıldız, Jale, Baysal, Nuran Ahu, İskender, Dicle, Çakar, Merih Kızıl, Dal, Mehmet Sinan, Hacıbekiroğlu, Tuba, and Altuntaş, Fevzi

Published
2020
Full Text
View/download PDF

31. Evaluation of oral manifestations and head and neck lymphadenopathy in newly diagnosed acute leukemia patients.

Author

Pamukcu, Umut, Dal, Mehmet Sinan, Yaman, Samet, Aslan Candır, Burcu, Bozan, Ersin, Secilmis, Sema, Acik Kemaloglu, Sibel, Altuntas, Fevzi, and Peker, Ilkay

Subjects
ACUTE leukemia, ORAL manifestations of general diseases, LYMPHOBLASTIC leukemia, LYMPHADENITIS, ACUTE myeloid leukemia, PAROTID glands
Abstract

Objectives: To determine the frequency of head and neck lymphadenopathy (LAP) and intraoral findings (non‐dental/dental) in patients with newly diagnosed acute leukemia (AL). Subjects and methods: Twenty‐eight (52.8%) females and 25 (47.2%) males in a total of 53 patients with newly diagnosed AL with a mean age of 46 years were included in the study. Personal information, the type of AL (AML [acute myelogenous leukemia]/ALL [acute lymphocytic leukemia]), and hematological findings (anemia, neutropenia, and thrombocytopenia) were obtained from medical records. One of two calibrated oral diagnosis and maxillofacial radiology specialists performed extraoral (head and neck LAPs) and intraoral (non‐dental and dental) clinical examinations. The Chi‐square (χ2) test was used to evaluate categorical variables. Results: LAP was observed in 22.6% and intraoral findings in 30.2% of the patients. LAP was most commonly observed in the neck and none in the parotid glands. The most intraoral findings were gingival/mucosal bleeding and oral petechiae/ecchymosis. While there was no statistical difference between AML and ALL patients in terms of LAP (p >.05), intraoral findings were observed more in patients with AML (p <.05). Only two (3.8%) patients had dental findings. With a slight difference, intraoral findings were more with thrombocytopenia and LAP with neutropenia. Conclusion: In AL, especially non‐dental intraoral findings are common. The fact that dentists working in the oral cavity are often the first specialists to encounter the oral manifestations of AL imposes an important role in early diagnosis and treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Turkey

Author

Tekinalp, Atakan, primary, Gedük, Ayfer, additional, Akdeniz, Aydan, additional, Terzi Demirsoy, Esra, additional, Gürsoy, Vildan, additional, Aslaner Ak, Müzeyyen, additional, Bağcı, Metin, additional, Seçilmiş, Sema, additional, Keklik Karadağ, Fatma, additional, Oruç Uysal, Ayşe, additional, Doğan, Ali, additional, Demircioğlu, Sinan, additional, Erol, Haşim Atakan, additional, Aslan, Ceyda, additional, Özkalemkaş, Fahir, additional, Ertop, Şehmus, additional, Dağlı, Mehmet, additional, Dal, Mehmet Sinan, additional, Saydam, Güray, additional, Merter, Mustafa, additional, Ural, Cihan, additional, and Çeneli, Özcan, additional

Published
2023
Full Text
View/download PDF

42. P1073: A NEW SCORING SYSTEM TO PREDICT SURVIVAL IN ELDERLY ADVANCED STAGE HODGKIN LYMPHOMA PATIENTS: STUDY BY TURKISH SOCIETY OF HAEMATOLOGY LYMPHOMA ACADEMY WORKING GROUP

Author

Mehtap, Özgür, primary, Toptas, Tayfur, additional, Sinan Dal, Mehmet, additional, Hayri Özsan, Güner, additional, Sayinalp, Nigün, additional, Saydam, Güray, additional, Ali Uçar, Mehmet, additional, Onur Kirgizlar, Hakki, additional, Salim, Ozan, additional, Tekinalp, Atakan, additional, Özkalemkaş, Fahir, additional, Pepedil Tanrikulu, Funda, additional, Meltem Akay, Olga, additional, Kiliçaslan, Emrah, additional, Paydas, Semra, additional, Civriz, Sinem, additional, Yilmaz, Mehmet, additional, Karakuş, Volkan, additional, Geçgel, Fatma, additional, Darçin, Tahir, additional, Erdoğan, Elçin, additional, Çinar, Erkin, additional, Keklik Karadağ, Fatma, additional, Ataş, Ünal, additional, Gürsoy, Vildan, additional, Sertaç Durusoy, Salih, additional, Birtaş Ateşoğlu, Elif, additional, Tombak, Anil, additional, Büyükkurt, Nurhilal, additional, Özcan, Muhit, additional, Altuntaş, Fevzi, additional, and Burhan Ferhanoğlu, Ahmet, additional

Published
2023
Full Text
View/download PDF

45. Glofitamab in relapsed/refractory diffuse large B‐cell lymphoma: Real‐world data

Author

Birtas Atesoglu, Elif, primary, Gulbas, Zafer, additional, Uzay, Ant, additional, Ozcan, Muhit, additional, Ozkalemkas, Fahir, additional, Dal, Mehmet Sinan, additional, Kalyon, Hakan, additional, Akay, Olga Meltem, additional, Deveci, Burak, additional, Bekoz, Huseyin, additional, Sevindik, Omur Gokmen, additional, Toptas, Tayfur, additional, Yilmaz, Fergun, additional, Koyun, Derya, additional, Alkis, Nihan, additional, Alacacioglu, Inci, additional, Sonmez, Mehmet, additional, Yavasoglu, Irfan, additional, Tombak, Anil, additional, Mehtap, Ozgur, additional, Kurnaz, Fatih, additional, Yuce, Orhan Kemal, additional, Karakus, Volkan, additional, Turgut, Mehmet, additional, Kurekci, Derya Deniz, additional, Ayer, Mesut, additional, Keklik, Muzaffer, additional, Buyuktas, Deram, additional, Ozbalak, Murat, additional, and Ferhanoglu, Burhan, additional

Published
2023
Full Text
View/download PDF

46. Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey

Author

Bakırtaş, Mehmet, primary, Dal, Mehmet Sinan, additional, Yiğenoğlu, Tuğçe Nur, additional, Giden, Asli Odabası, additional, Serin, Istemi, additional, Başcı, Semih, additional, Kalpakci, Yasin, additional, Korkmaz, Serdal, additional, Ekinci, Omer, additional, Albayrak, Murat, additional, Basturk, Abdulkadir, additional, Ozatli, Duzgun, additional, Dogu, Mehmet Hilmi, additional, Hacıbekiroglu, Tuba, additional, Çakar, Merih Kızıl, additional, Ulas, Turgay, additional, Miskioglu, Mine, additional, Gulturk, Emine, additional, Eser, Bulent, additional, and Altuntas, Fevzi, additional

Published
2023
Full Text
View/download PDF

49. The Turkish perspective on apheresis activity: The Turkish apheresis registry report

Author

Akdeniz, Aydan, Basci, Semih, Ulas, Turgay, Turgut, Burhan, Yigenoglu, Tugce Nur, Hacibekiroglu, Tuba, Basturk, Abdulkadir, Dal, Mehmet Sinan, Namdaroglu, Sinem, Hindilerden, Fehmi, Hacioglu, Sibel Kabukcu, Cagliyan, Gulsum Akgun, Ilhan, Gul, Kacmaz, Murat, Uysal, Ayşe, Merter, Mustafa, Ekinci, Omer, Dursun, Fadime Ersoy, Tekinalp, Atakan, Demircioglu, Sinan, Sincan, Gulden, Acik, Didar Yanardag, Korkmaz, Serdal, Ucar, Mehmet Ali, Yeral, Mahmut, Ciftciler, Rafiye, Teke, Hava Uskudar, Umit, Elif Gulsum, Karakus, Abdullah, Bilen, Yusuf, Yokus, Osman, Albayrak, Murat, Demir, Cengiz, Okan, Vahap, Serefhanoglu, Songül, Kartı, Sami, Ozkurt, Zubeyde Nur, Eser, Bulent, Aydogdu, Ismet, Kuku, Irfan, Cagirgan, Seckin, Sonmez, Mehmet, Ozet, Gulsum, Altuntas, Fevzi, ERKURT, MEHMET ALİ, Giden, Aslı Odabaşı, and Ozatli, Duzgun

Abstract

Therapeutic apheresis is an extracorporeal treatment that selectively removes abnormal cells or harmful substances in the blood that are associated with or cause certain diseases. During the last decades the application of therapeutic apheresis has expanded to a broad spectrum of hematological and non-hematological diseases due to various studies on the clinical efficacy of this procedure. In this context there are more than 30 centers performing therapeutic apheresis and registered in the apheresis database in Turkey. Herein, we, The Turkish Apheresis Registry, aimed to analyze some key articles published so far from Turkey regarding the use of apheresis for various indications.

Published
2023

50. Evaluation of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus seroprevalence in patients with diffuse large B cell lymphoma and Hodgkin's lymphoma

Author

Mert, Duygu, Merdin, Alparslan, Ceken, Sabahat, Dal, Mehmet, Ertek, Mustafa, and Altuntas, Fevzi

Subjects
Non-Hodgkin's lymphomas -- Risk factors -- Development and progression, Hodgkin's disease -- Risk factors -- Development and progression, Hepatitis B -- Complications and side effects -- Physiological aspects, Hepatitis C -- Complications and side effects -- Physiological aspects, HIV infection -- Complications and side effects -- Physiological aspects, Health
Abstract

Byline: Duygu. Mert, Alparslan. Merdin, Sabahat. Ceken, Mehmet. Dal, Mustafa. Ertek, Fevzi. Altuntas Backgrounds: Non-Hodgkin's lymphoma and Hodgkin's lymphomas (HL) are lymphoid neoplasms. Hepatitis B virus (HBV), hepatitis C virus [...]

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results